Swaza is developing the first nanofluid breathing aid to treat acute oxygen loss. Our vision is to create a portable breathing aid that's affordable and easy to use, and that could be quickly deployed to combat hypoxemia worldwide. Our technology repurposes previously approved pharmaceutical ingredients into a new nanofluid designed to aid gas exchange—even in inflamed or fluid-filled lungs.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2022
Main Therapeutic Focus:
Respiratory
Lead Product in Development:
SWAZA-1 Nanofluid
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2